# reload+after+2024-01-19 22:47:44.312177
address1§4300 El Camino Real
address2§Suite 210
city§Los Altos
state§CA
zip§94022
country§United States
phone§650 351 4495
website§https://unicycive.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Shalabh K. Gupta M.D., MPA', 'age': 50, 'title': 'Founder, Chairman, CEO & President', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1458012, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pramod  Gupta Ph.D.', 'age': 63, 'title': 'Executive Vice President of Pharmaceutical & Business Operations', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 779178, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas  Jermasek M.B.A.', 'age': 62, 'title': 'Executive Vice President of Corporate Strategy', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 430808, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John W. Townsend CPA', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 197864, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.527
priceToSalesTrailing12Months§43.24992
currency§USD
dateShortInterest§1702598400
forwardEps§-0.39
exchange§NCM
quoteType§EQUITY
shortName§Unicycive Therapeutics, Inc.
longName§Unicycive Therapeutics, Inc.
firstTradeDateEpochUtc§1626096600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8b289956-33cd-3aa2-beed-9487631afaeb
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.5
targetLowPrice§3.0
targetMeanPrice§3.83
targetMedianPrice§4.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.928
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
